ALNYLAM PHARMACEUTICALS, INC. (ALNY) — Institutional Holders, Q2 2026 (page 9)

811 institutional investment managers reported a ALNY position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $40.5B. Every filer is listed below, ranked by position value, 100 per page; this page shows ranks 801 to 811. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.

ALNY 13F holders ranked 801–811 of 811

Institutional investors reporting a position in ALNYLAM PHARMACEUTICALS, INC. on SEC Form 13F-HR for Q2 2026, ranked by reported value.
InstitutionValueQoQ
Stone House Investment Management#801 · 1 sh$301.000.0%
Atlantic Private Wealth#802 · 1 sh$301.000.0%
Decker Retirement Planning#803 · 1 sh$301.00New
Glen Eagle Advisors#804 · 1 sh$301.000.0%
ROSS\JOHNSON & Associates#805 · 1 sh$301.000.0%
CREATIVE FINANCIAL DESIGNS#806 · 1 sh$301.000.0%
Cordant#807 · 1 sh$223.00New
Darwin Wealth Management#808 · 0 sh$198.00New
Navigoe#809 · 1 sh$0.00New
OGOREK ANTHONY JOSEPH /NY#810 · 3 sh$0.000.0%
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM#811 · 199,861 sh—+1.5%

Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.